Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 5/20 | 0.62 |
| ▸ | GCGR | P47871 | 1/20 | 0.62 |
| ▸ | GIPR | P48546 | 1/20 | 0.62 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.59 |
| ▸ | PTH1R | Q03431 | 3/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.53 |
| ▸ | CCKBR | P32239 | 1/20 | 0.53 |
| ▸ | TLR2 | O60603 | 1/20 | 0.53 |
| ▸ | GHSR | Q92847 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30601285 | 0.90 | GLP1R (0.64) | GLP1RGCGRGIPRIL23RPTH1R | |
| SCHEMBL30262119 | 0.90 | GLP1R (0.62) | GLP1RGCGRGIPRIL23RPTH1R | |
| SCHEMBL29608081 | 0.89 | GLP1R (0.62) | GLP1RGCGRGIPRIL23RPTH1R | |
| SCHEMBL29855839 | 0.87 | ERAP2 (0.60) | GLP1RKISS1RTLR2 | |
| SCHEMBL29525144 | 0.85 | GLP1R (0.68) | GLP1RGCGRGIPRIL23RPTH1R | |
| SCHEMBL30512698 | 0.85 | ERBB2 (0.65) | GLP1RGCGRGIPRIL23RKISS1R | |
| SCHEMBL31532229 | 0.85 | KISS1R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL33533126 | 0.85 | ERAP2 (0.56) | GLP1RGCGRGIPRKISS1R | |
| SCHEMBL30398271 | 0.85 | ERAP2 (0.56) | GLP1RGCGRGIPRKISS1R | |
| SCHEMBL31666086 | 0.85 | IL23R (0.66) | GLP1RGCGRGIPRIL23RCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267193-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | Ludwig-Maximilians-Universität München (DE) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022136555-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-30 | — | — | WO | disclosed |